Skip to main content

IMPAACT4HIV

Opportunistic Infections

On this page, explore how research drives progress in AHD care — with access to key studies, clinical trial results, guidelines, and insights shaping policy and practice across sub-Saharan Africa.

This page offers clinical resources, training tools, patient support, policy content, multimedia, and accessibility features — all designed to support comprehensive care and education.

Prevalence of advanced HIV disease and associated factors among antiretroviral therapy naïve adults enrolling in care at public health facilities in Kampala, Uganda

Bridget Ainembabazi 1, Elizabeth Katana 2, Felix Bongomin 3 4, Phillip Wanduru 5 6, Roy William Mayega 1, Aggrey David Mukose 1

 

Affiliations + Expand

 

 

Abstract

 

Background: Despite adoption of the ‘test-and-treat’ strategy, a high proportion of antiretroviral therapy (ART) naïve people living with HIV (PLHIV) enrol in care with, and die of advanced HIV disease (AHD) in Uganda. In this study, we aimed to determine the prevalence of AHD among ART naïve adults enrolling in care and associated factors at selected public health facilities in Kampala, Uganda.

 

Methods: From April to July 2022, we conducted a mixed-methods study at Kiswa Health Centre III, Kitebi Health Centre III, and Kawaala Health Centre IV. The study involved cross-sectional enrolment and evaluation of 581 participants, utilizing an interviewer-administered questionnaire and chart reviews. Modified Poisson regression was employed to identify factors associated with AHD, complemented by a qualitative component comprising fifteen in-depth interviews, with data analysed through thematic analysis.

 

Results: Overall, 35.1% (204/581) of the study participants had AHD. Being male [adjusted prevalence ratio (aPR): 1.4, 95% CI: 1.04-1.88] and aged 35-50 years (aPR: 1.81, 95% CI: 1.14-2.88) were associated with AHD. Participants with no personal health perception barriers had 37% lower odds of presenting to care with AHD (aPR: 0.63, 95% CI: 0.46-0.85). Qualitative findings indicated that individual factors, such as waiting until physical health deteriorated and initially opting for alternative therapies, took precedence in contributing to enrolment in care with AHD.

 

Conclusion: Over one in every three ART naïve adults presents to public health facilities in Uganda with AHD. Male gender, age 35-50 years, and personal health perception barriers emerged as significant factors associated with AHD; emphasizing the need for targeted interventions to address these disparities and enhance early detection and engagement in care. Routine HIV testing should be emphasized and incentivized especially for men and persons aged 35-50 years.

 

Keywords: Kampala; PLHIV; advanced HIV disease; antiretroviral therapy naïve; test and treat.

 

 

Cited by

 

References

  • UNAIDS. FACT SHEET Global HIV statistics [Internet], https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_… (2023, accessed 26 November 2023).
  • UNAIDS. Country factsheets UGANDA 2022 [Internet]. HIV and AIDS estimates, https://www.unaids.org/en/regionscountries/countries/uganda (2022, accessed 26 November 2023).
  • World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland 2015. – PubMed
  • Lundgren JD, Babiker AG, Gordin F, et al.. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795–807. – PMC – PubMed
  • Danel C, Moh R, Gabillard D, et al.. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373: 808–822. – PubMed
  • World Health Organization. HIV treatment: guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy: policy brief. Geneza: World Health Organization, 2017. – PubMed
  • UNAIDS. The path that ends AIDS. Geneva, Switzerland: UNAIDS, 2023.
  • UNAIDS. Fast track commitments to end AIDS by 2030 [Internet], https://www.unaids.org/sites/default/files/media_asset/fast-track-commit… (2021, accessed 26 November 2023).
  • Hogg RS, Yip B, Chan KJ, et al.. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568–2577. – PubMed
  • Egger M, May M, Chêne G, et al.. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119–129. – PubMed
  • Bennett S, Woods T, Liyanage WM, et al.. A simplified general method for cluster-sample surveys of health in developing countries. World Heal Stat Q 1991; 44: 98–106. – PubMed
  • Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702–706. – PubMed
  • Wilber ST, Fu R. Risk ratios and odds ratios for common events in cross-sectional and cohort studies. Acad Emerg Med 2010; 17: 649–651. – PubMed
  • Coutinho L, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica 2008; 42: 992–998. – PubMed
  • Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77–101.
  • Von Elm E, Altman DG, Egger M, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 : 1453–1457. – PubMed
  • Lebelonyane R, Mills LA, Mogorosi C, et al.. Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes. AIDS 2020; 34: 2223–2230. – PubMed
  • Oboho I, Esber AL, Dear N, et al.. 113. Advanced HIV disease among adults in the African Cohort Study (AFRICOS). In: Open forum infectious diseases. Oxford: Oxford University Press, 2020, pp. S185–S185.
  • Benzekri NA, Sambou JF, Ndong S, et al.. Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa. BMC Infect Dis 2019; 19: 1–8. – PMC – PubMed
  • Lifson AR, Workneh S, Hailemichael A, et al.. Advanced HIV disease among males and females initiating HIV care in rural Ethiopia. J Int Assoc Provid AIDS Care 2019; 18: 2325958219847199. – PMC – PubMed
  • Delpierre C, Dray-Spira R, Cuzin L, et al.. Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS 2007; 18: 312–317. – PMC – PubMed
  • Trepka MJ, Fennie KP, Sheehan DM, et al.. Late HIV diagnosis: differences by rural/urban residence, Florida, 2007–2011. AIDS Patient Care STDS 2014; 28: 188–197. – PMC – PubMed
  • Chikovore J, Gillespie N, McGrath N, et al.. Men, masculinity, and engagement with treatment as prevention in KwaZulu-Natal, South Africa. AIDS Care 2016; 28(Suppl. 3): 74–82. – PMC – PubMed
  • Treves-Kagan S, El Ayadi AM, Pettifor A, et al.. Gender, HIV testing and stigma: the association of HIV testing behaviors and community-level and individual-level stigma in rural South Africa differ for men and women. AIDS Behav 2017; 21: 2579–2588. – PMC – PubMed
  • Mills EJ, Bakanda C, Birungi J, et al.. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011; 14: 1–7. – PMC – PubMed
  • Mane P, Aggleton P. Gender and HIV/AIDS: what do men have to do with it? Curr Sociol 2001; 49: 23–37.
  • Pe R, Chim B, Thai S, et al.. Advanced HIV disease at enrolment in HIV care: trends and associated factors over a ten year period in Cambodia. PLoS One 2015; 10(11): e0143320. – PMC – PubMed
  • Lofgren SM, Tsui S, Natala N, et al.. Differences in reasons for late presentation to HIV care in Uganda among men and women. AIDS Behav 2023; 27: 303–313. – PMC – PubMed
  • Wanyenze RK, Kamya MR, Fatch R, et al.. Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One 2011; 6: e21794. – PMC – PubMed
  • Namuddu B, Kalyango JN, Karamagi C, et al.. Prevalence and factors associated with traditional herbal medicine use among patients on highly active antiretroviral therapy in Uganda. BMC Public Health 2011; 11: 1–9. – PMC – PubMed
  • Lamorde M, Tabuti JRS, Obua C, et al.. Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. J Ethnopharmacol 2010; 130: 43–53. – PubMed
  • Langlois-Klassen D, Kipp W, Jhangri GS, et al.. Use of traditional herbal medicine by AIDS patients in Kabarole District, western Uganda. Am J Trop Med Hyg 2007; 77: 757. – PubMed
  • Anywar G, Kakudidi E, Byamukama R, et al.. Medicinal plants used by traditional medicine practitioners to boost the immune system in people living with HIV/AIDS in Uganda. Eur J Integr Med 2020; 35: 101011.
  • Kiguba R, Byakika-Tusiime J, Karamagi C, et al.. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. JAIDS J Acquir Immune Defic Syndr 2007; 45: 218–223. – PubMed\

       

      Related information

       

      LinkOut – more resources

      Solverwp- WordPress Theme and Plugin